AstraZeneca reported that high-level data analysis from the company’s Phase III CASPIAN trial demonstrated that Imfinzi (durvalumab) in combination with standard-of-care chemotherapies confirmed a clinically meaningful and sustained overall survival benefit in patients with extensive-stage small cell lung cancer treated in the first-line setting.
Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.
New results from the NURTURE study demonstrate that pre-symptomatic infants treated with Spinraza are achieving motor milestones that are unprecedented in the natural history of the disease.
Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.
An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.
Seattle Genetics and development partner Takeda Pharmaceutical announced stellar Phase III data from the ECHELON-2 clinical trial of Adcetris (brentuximab vedotin) for peripheral T-cell lymphoma.
Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.